AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. DXR
  4. [Form 4] Daxor Corporation Insider Trading Activity

[Form 4] Daxor Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Daxor (NASDAQ:DXR) filed a Form 4 reporting the grant of 2,500 non-qualified stock options to director Joy S. Goudie on June 24 2025 at an exercise price of $9.29 per share, expiring June 24 2030.

The award is contingent upon SEC approval of an amendment to the company鈥檚 2020 Incentive Compensation Plan and vests in three tranches: 833 options on June 24 2025, 883 on June 24 2026, and 834 on June 24 2027. No open-market purchases or sales were disclosed; the filing solely records the new derivative position. Following the transaction, Goudie beneficially owns 2,500 options with no change to her reported direct share ownership.

Daxor (NASDAQ:DXR) ha presentato un Modulo 4 segnalando la concessione di 2.500 opzioni azionarie non qualificate alla direttrice Joy S. Goudie il 24 giugno 2025 a un prezzo di esercizio di 9,29 $ per azione, con scadenza il 24 giugno 2030.

Il premio 猫 subordinato all'approvazione da parte della SEC di una modifica al Piano di Incentivi 2020 della societ脿 e si consolida in tre tranche: 833 opzioni il 24 giugno 2025, 883 il 24 giugno 2026 e 834 il 24 giugno 2027. Non sono stati comunicati acquisti o vendite sul mercato aperto; la segnalazione registra esclusivamente la nuova posizione derivata. Dopo la transazione, Goudie detiene beneficiariamente 2.500 opzioni senza variazioni nella sua propriet脿 diretta di azioni riportata.

Daxor (NASDAQ:DXR) present贸 un Formulario 4 reportando la concesi贸n de 2.500 opciones sobre acciones no calificadas a la directora Joy S. Goudie el 24 de junio de 2025 a un precio de ejercicio de $9,29 por acci贸n, con vencimiento el 24 de junio de 2030.

La concesi贸n est谩 condicionada a la aprobaci贸n de la SEC de una enmienda al Plan de Compensaci贸n Incentivada 2020 de la compa帽铆a y se otorga en tres tramos: 833 opciones el 24 de junio de 2025, 883 el 24 de junio de 2026 y 834 el 24 de junio de 2027. No se divulgaron compras o ventas en el mercado abierto; la presentaci贸n solo registra la nueva posici贸n derivada. Tras la transacci贸n, Goudie posee beneficiosamente 2.500 opciones sin cambios en su propiedad directa reportada de acciones.

Daxor (NASDAQ:DXR)電� 鞚挫偓 Joy S. Goudie鞐愱矊 2,500臧滌潣 牍勳瀽瓴� 欤检嫕 鞓奠厴鞚� 2025雲� 6鞗� 24鞚检棎 頄夓偓臧�瓴� 欤茧嫻 $9.29搿� 攵�鞐枅鞚岇潉 氤搓碃頃橂姅 Form 4毳� 鞝滌稖頄堨溂氅�, 毵岆鞚检潃 2030雲� 6鞗� 24鞚�鞛呺媹雼�.

鞚� 靾橃棳電� 須岇偓鞚� 2020雲� 鞚胳劶韹半笇 氤挫儊 瓿勴殟 靾橃爼鞎堨棎 雽�頃� SEC 鞀轨澑鞐� 霐半澕 雼澕歆�氅�, 靹� 氩堨棎 雮橂垊鞏� 甓岆Μ臧� 攵�鞐惄雼堧嫟: 2025雲� 6鞗� 24鞚检棎 833 鞓奠厴, 2026雲� 6鞗� 24鞚检棎 883 鞓奠厴, 2027雲� 6鞗� 24鞚检棎 834 鞓奠厴. 瓿店皽 鞁滌灔鞐愳劀鞚� 毵るГ電� 鞐嗢棃鞙茧┌, 鞚措矆 鞝滌稖鞚� 靸堧鞖� 韺岇儩靸來拡 韽靺橂鞚� 旮半頃╇媹雼�. 瓯半灅 頉� Goudie電� 氤搓碃霅� 歆侅爲 欤检嫕 靻岇湢鞐愲姅 氤�霃� 鞐嗢澊 2,500 鞓奠厴鞚� 鞁れ鞝侅溂搿� 氤挫湢頃橁矊 霅╇媹雼�.

Daxor (NASDAQ:DXR) a d茅pos茅 un formulaire 4 signalant l'attribution de 2 500 options d'achat d'actions non qualifi茅es 脿 la directrice Joy S. Goudie le 24 juin 2025, 脿 un prix d'exercice de 9,29 $ par action, avec expiration le 24 juin 2030.

Cette attribution est conditionn茅e 脿 l'approbation par la SEC d'un amendement au Plan de R茅mun茅ration Incitative 2020 de la soci茅t茅 et se d茅compose en trois tranches : 833 options le 24 juin 2025, 883 le 24 juin 2026 et 834 le 24 juin 2027. Aucun achat ou vente sur le march茅 ouvert n'a 茅t茅 divulgu茅 ; le d茅p么t enregistre uniquement la nouvelle position d茅riv茅e. Apr猫s la transaction, Goudie d茅tient effectivement 2 500 options sans changement dans sa propri茅t茅 directe d'actions d茅clar茅e.

Daxor (NASDAQ:DXR) reichte ein Formular 4 ein und meldete die Gew盲hrung von 2.500 nicht qualifizierten Aktienoptionen an die Direktorin Joy S. Goudie am 24. Juni 2025 zu einem Aus眉bungspreis von 9,29 $ pro Aktie mit Ablaufdatum 24. Juni 2030.

Die Zuteilung ist abh盲ngig von der Genehmigung der SEC einer 脛nderung des Incentive Compensation Plans 2020 des Unternehmens und erfolgt in drei Tranchen: 833 Optionen am 24. Juni 2025, 883 am 24. Juni 2026 und 834 am 24. Juni 2027. Keine K盲ufe oder Verk盲ufe am offenen Markt wurden offengelegt; die Meldung dokumentiert ausschlie脽lich die neue Derivatposition. Nach der Transaktion besitzt Goudie wirtschaftlich 2.500 Optionen ohne 脛nderung ihres gemeldeten direkten Aktienbesitzes.

Positive
  • None.
Negative
  • None.

Daxor (NASDAQ:DXR) ha presentato un Modulo 4 segnalando la concessione di 2.500 opzioni azionarie non qualificate alla direttrice Joy S. Goudie il 24 giugno 2025 a un prezzo di esercizio di 9,29 $ per azione, con scadenza il 24 giugno 2030.

Il premio 猫 subordinato all'approvazione da parte della SEC di una modifica al Piano di Incentivi 2020 della societ脿 e si consolida in tre tranche: 833 opzioni il 24 giugno 2025, 883 il 24 giugno 2026 e 834 il 24 giugno 2027. Non sono stati comunicati acquisti o vendite sul mercato aperto; la segnalazione registra esclusivamente la nuova posizione derivata. Dopo la transazione, Goudie detiene beneficiariamente 2.500 opzioni senza variazioni nella sua propriet脿 diretta di azioni riportata.

Daxor (NASDAQ:DXR) present贸 un Formulario 4 reportando la concesi贸n de 2.500 opciones sobre acciones no calificadas a la directora Joy S. Goudie el 24 de junio de 2025 a un precio de ejercicio de $9,29 por acci贸n, con vencimiento el 24 de junio de 2030.

La concesi贸n est谩 condicionada a la aprobaci贸n de la SEC de una enmienda al Plan de Compensaci贸n Incentivada 2020 de la compa帽铆a y se otorga en tres tramos: 833 opciones el 24 de junio de 2025, 883 el 24 de junio de 2026 y 834 el 24 de junio de 2027. No se divulgaron compras o ventas en el mercado abierto; la presentaci贸n solo registra la nueva posici贸n derivada. Tras la transacci贸n, Goudie posee beneficiosamente 2.500 opciones sin cambios en su propiedad directa reportada de acciones.

Daxor (NASDAQ:DXR)電� 鞚挫偓 Joy S. Goudie鞐愱矊 2,500臧滌潣 牍勳瀽瓴� 欤检嫕 鞓奠厴鞚� 2025雲� 6鞗� 24鞚检棎 頄夓偓臧�瓴� 欤茧嫻 $9.29搿� 攵�鞐枅鞚岇潉 氤搓碃頃橂姅 Form 4毳� 鞝滌稖頄堨溂氅�, 毵岆鞚检潃 2030雲� 6鞗� 24鞚�鞛呺媹雼�.

鞚� 靾橃棳電� 須岇偓鞚� 2020雲� 鞚胳劶韹半笇 氤挫儊 瓿勴殟 靾橃爼鞎堨棎 雽�頃� SEC 鞀轨澑鞐� 霐半澕 雼澕歆�氅�, 靹� 氩堨棎 雮橂垊鞏� 甓岆Μ臧� 攵�鞐惄雼堧嫟: 2025雲� 6鞗� 24鞚检棎 833 鞓奠厴, 2026雲� 6鞗� 24鞚检棎 883 鞓奠厴, 2027雲� 6鞗� 24鞚检棎 834 鞓奠厴. 瓿店皽 鞁滌灔鞐愳劀鞚� 毵るГ電� 鞐嗢棃鞙茧┌, 鞚措矆 鞝滌稖鞚� 靸堧鞖� 韺岇儩靸來拡 韽靺橂鞚� 旮半頃╇媹雼�. 瓯半灅 頉� Goudie電� 氤搓碃霅� 歆侅爲 欤检嫕 靻岇湢鞐愲姅 氤�霃� 鞐嗢澊 2,500 鞓奠厴鞚� 鞁れ鞝侅溂搿� 氤挫湢頃橁矊 霅╇媹雼�.

Daxor (NASDAQ:DXR) a d茅pos茅 un formulaire 4 signalant l'attribution de 2 500 options d'achat d'actions non qualifi茅es 脿 la directrice Joy S. Goudie le 24 juin 2025, 脿 un prix d'exercice de 9,29 $ par action, avec expiration le 24 juin 2030.

Cette attribution est conditionn茅e 脿 l'approbation par la SEC d'un amendement au Plan de R茅mun茅ration Incitative 2020 de la soci茅t茅 et se d茅compose en trois tranches : 833 options le 24 juin 2025, 883 le 24 juin 2026 et 834 le 24 juin 2027. Aucun achat ou vente sur le march茅 ouvert n'a 茅t茅 divulgu茅 ; le d茅p么t enregistre uniquement la nouvelle position d茅riv茅e. Apr猫s la transaction, Goudie d茅tient effectivement 2 500 options sans changement dans sa propri茅t茅 directe d'actions d茅clar茅e.

Daxor (NASDAQ:DXR) reichte ein Formular 4 ein und meldete die Gew盲hrung von 2.500 nicht qualifizierten Aktienoptionen an die Direktorin Joy S. Goudie am 24. Juni 2025 zu einem Aus眉bungspreis von 9,29 $ pro Aktie mit Ablaufdatum 24. Juni 2030.

Die Zuteilung ist abh盲ngig von der Genehmigung der SEC einer 脛nderung des Incentive Compensation Plans 2020 des Unternehmens und erfolgt in drei Tranchen: 833 Optionen am 24. Juni 2025, 883 am 24. Juni 2026 und 834 am 24. Juni 2027. Keine K盲ufe oder Verk盲ufe am offenen Markt wurden offengelegt; die Meldung dokumentiert ausschlie脽lich die neue Derivatposition. Nach der Transaktion besitzt Goudie wirtschaftlich 2.500 Optionen ohne 脛nderung ihres gemeldeten direkten Aktienbesitzes.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Goudie Joy S.
(Last) (First) (Middle)
109 MECO LANE
(Street)
OAK RIDGE, TN 37830
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DAXOR CORP [ DXR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (right to buy) $9.29 06/24/2025(1) A 2,500 (2) 06/24/2030 COMMON STOCK 2,500 $0 2,500 D
Explanation of Responses:
1. Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").
2. The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834)
/s/ Joy Goudie 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many stock options did DXR grant to director Joy S. Goudie?

The Form 4 shows a grant of 2,500 stock options with a strike price of $9.29 per share.

What is the vesting schedule for Joy Goudie鈥檚 2,500 DXR options?

The options vest in three installments: 833 on 6/24/2025, 883 on 6/24/2026, and 834 on 6/24/2027.

Are the granted options subject to any conditions?

Yes. The grant is contingent upon SEC approval to amend Daxor鈥檚 2020 Incentive Compensation Plan.

Did the filing report any purchase or sale of DXR shares?

No. The Form 4 only discloses the option grant; no shares were bought or sold.
Stock DXR logo
DAXOR CORP

NASDAQ:DXR

DXR Rankings

#7933 Ranked by Market Cap
N/A Ranked by Dividends

DXR Latest News

Aug 7, 2025
Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
Jul 22, 2025
Daxor鈥檚 Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
May 14, 2025
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
May 13, 2025
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems
May 7, 2025
Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology

DXR Latest SEC Filings

Aug 7, 2025
[8-K] Daxor Corporation Reports Material Event
Jul 24, 2025
[N-CEN/A] Daxor Corporation SEC Filing
Jul 24, 2025
[N-CEN/A] Daxor Corporation SEC Filing
Jul 1, 2025
[8-K] Daxor Corporation Reports Material Event
Jun 26, 2025
[Form 4] Daxor Corporation Insider Trading Activity

DXR Stock Data

49.62M
2.14M
56.9%
1.96%
0.22%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
United States
NEW YORK